Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 HKD | -1.41% | -4.76% | -64.56% |
04-29 | Zhaoke Ophthalmology Shrinks Loss in 2023 | MT |
04-08 | Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-64.56% | 97.88M | - | ||
+50.70% | 791B | C+ | ||
+41.96% | 630B | B | ||
-7.15% | 350B | C+ | ||
+18.77% | 328B | B- | ||
+8.79% | 298B | C+ | ||
+18.02% | 246B | B+ | ||
+1.27% | 225B | A+ | ||
+11.95% | 218B | B- | ||
+3.68% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6622 Stock
- Ratings Zhaoke Ophthalmology Limited